Serum interleukin measurement may help identify thyroid cancer patients with active disease

Author(s)

Martins, Mariana Bonjiorno ^[1] ; Marcello, Marjory Alana ^[1] ; Batista, Fernando de Assis ^[1] ; Peres, Karina Colombera ^[1] ; Meneghetti, Murilo ^[1] ; Latham Ward, Mirela Andrea ^[1] ; Sa de Camargo Etchebehere, Elba Cristina ^[2] ; Montali da Assumpcao, Ligia Vera ^[3] ; Ward, Laura Sterian ^[1]

Affiliation

^[1] Univ Campinas Unicamp, Fac Med Sci FCM, Lab Canc Mol Genet, 126 Tessalia Vieira Camargo St, Campinas, SP - Brazil

^[2] Univ Campinas Unicamp, Fac Med Sci FCM, Dept Radiol, Div Nucl Med, 251 Vital Brazil St, Campinas, SP - Brazil

^[3] Univ Campinas Unicamp, Fac Med Sci FCM, Dept Med, Div Endocrinol, 251 Vital Brazil St, Campinas, SP - Brazil

• Document type: Journal article
• Source: CLINICAL BIOCHEMISTRY; v. 52, p. 1-7, FEB 2018.
• Web of Science Citations: 4

Abstract

Background: Investigate the clinical utility of serum interleukin dosages of IL-2, IL-2R, IL-4, IL-6, IL-6R, IL-8, IL10 and IL-12 in the diagnosis and characterization of patients with DTC. In particular, verify ILs utility in the identification of individuals who are evolving disease-free or with the active disease. Methods: We evaluated 200 patients with malignant nodules (100 patients disease-free and 100 patients with recurrence/active disease); 60 benign nodules and 100 healthy controls, serum levels were assessed by ELISA. Results: All ILs, but not IL-4, differentiated these three groups. We observed that IL-2, 2R and 10 serum concentrations were associated with thyroglobulin levels. Serum IL-2 was able to differentiate patients with active disease from the disease-free with a sensitivity of 98%, specificity of 58%, positive predictive value (PPV) of 70% and negative predictive value (NPV) of 97% (p = 0.0007). IL-6R levels differentiated patients with active disease from the disease-free patients with 56% sensitivity, 63% specificity, PPV of 60% and NPV of 59% (p < 0.0001). IL-8 values also distinguished patients with active disease from the disease-free ones with sensitivity of 50%, specificity of 76%, PPV of 68% and NPV of 60% (p = 0.0025); using IL-12, we obtained a sensitivity value of 73%, specificity of 66%, PPV of 68% and NPV of 71% (p < 0.0001). Furthermore, interleukin levels showed association with some tumor characteristics of aggressiveness. Conclusion: We suggest that the serum concentration of ILs may assist in the diagnosis and characterization of tumor malignancy helping identify patients with active disease who deserve closer medical attention. (AU)

• FAPESP's process: 12/22726-0 - Analysis of pro-inflammatory interleukins (IL-2, IL-2R, IL-6, IL-6R, IL-8, IL-12 A and B) and anti-inflammatory (IL-4, IL-4R, IL-10) in the differentiated thyroid carcinoma
• Grantee: Laura Sterian
• Support Opportunities: Regular Research Grants
• FAPESP's process: 12/16830-0 - ANALYSIS OF SERUM INTERLEUKINS IL-2, IL-4, IL-4R (RECEPTOR), IL-6, IL-6R (RECEPTOR), IL-8, IL-10, IL-12 (A,B) IN THE CLINICOPATHOLOGICAL PROFILE OF DIFFERENTIATED THYROID CARCINOMA.
• Grantee: Mariana Bonjiorno Martins
• Support Opportunities: Scholarships in Brazil - Doctorate